<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Canadian Cardiovascular Society (CCS) published the complete set of 2010 <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> (AF) Guidelines in the January, 2011 issue of the Canadian Journal of Cardiology </plain></SENT>
<SENT sid="1" pm="."><plain>During its deliberations, the CCS Guidelines Committee engaged to a timely review of future evidence, with periodic composition of focused updates to address clinically important advances </plain></SENT>
<SENT sid="2" pm="."><plain>In 2011, results were published from 3 pivotal AF trials: the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with <z:chebi fb="6" ids="28384">Vitamin K</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> for Prevention of <z:hpo ids='HP_0001297'>Stroke</z:hpo> and Embolism Trial in <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> (ROCKET-AF), the Apixaban for Reduction in <z:hpo ids='HP_0001297'>Stroke</z:hpo> and Other <z:hpo ids='HP_0001907'>Thromboembolic Events</z:hpo> in <z:hpo ids='HP_0005110'>Atrial Fibrillation</z:hpo> (ARISTOTLE) study, and the <z:hpo ids='HP_0004754'>Permanent Atrial Fibrillation</z:hpo> Outcome Study Using <z:chebi fb="0" ids="50659">Dronedarone</z:chebi> on Top of Standard Therapy (PALLAS), comparing <z:chebi fb="0" ids="50659">dronedarone</z:chebi> with placebo in patients with permanent AF and additional <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk-factor burden </plain></SENT>
<SENT sid="3" pm="."><plain>Each of these large randomized trials provided clear results with major implications for AF management </plain></SENT>
<SENT sid="4" pm="."><plain>Other important evidence that has emerged since the 2010 Guidelines includes findings about prediction instruments for AF-associated <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mp ids='MP_0001914'>bleeding</z:mp> risk, <z:hpo ids='HP_0001297'>stroke</z:hpo> risk in paroxysmal-AF patients, risk-benefit considerations related to oral anticoagulation in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e>, and risk/benefit considerations in the use of antiplatelet agents, alone and in combination with each other or with oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, in AF patients </plain></SENT>
<SENT sid="5" pm="."><plain>The Guidelines Committee judged that this extensive and important new evidence required focused updating of the 2010 Guidelines with respect to <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention and rate/rhythm control </plain></SENT>
<SENT sid="6" pm="."><plain>This report presents the details of the new recommendations, along with the background and rationale </plain></SENT>
</text></document>